Q-omics provides the consensus-scored MIR99B profile across patient tissues and cancer cell-line models. MIR99B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MIR99B is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, MIR99B RNA expression shows 5,355 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight BRCA, THCA, and OV as cancer lineages where MIR99B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR99B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR99B survival associations across molecular data types. MIR99B RNA expression shows survival associations in the most cancer types (16), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR99B RNA expression–survival associations across cancer types. High MIR99B expression shows unfavorable associations in BRCA, COAD, LIHC, MESO, UVM and KICH. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MIR99B RNA expression.
This table summarizes MIR99B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR99B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR99B shows lower tumor expression in THCA. The THCA box plot shows higher MIR99B RNA expression in normal versus tumor tissue (log2 FC = −0.772, t-test p = .046).
This table shows molecular features associated with MIR99B in patient tissues and cancer cell lines. In patient samples, MIR99B shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
